ClinicalTrials.gg
CompletedNCT01444417Updated Feb 9, 2017Results posted

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

A Phase 3 interventional study of Romiplostim and Placebo in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed at 33 sites in 3 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
15th of 29
62 · median 62
Started
2012
the only one that year
Phase 3
13 of 29
1 open now
Registered
14th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 15th largest by enrollment, is the only one that started in 2012, is one of 13 in phase 3, and was the 14th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric patients with Immune thrombocytopenia purpura (ITP) as measured by durable platelet response.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Thrombocytopenia
  • Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenic Purpura
  • Immune Thrombocytopenia

Keywords

  • Immune (Idiopathic) Thrombocytopenic Purpura
  • Pediatric Immune (Idiopathic) Thrombocytopenic Purpura
  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary ITP according to the American Society of Hematology (ASH) guidelines at least 6 months prior to screening, regardless of splenectomy status
  • Subject must be to a prior ITP therapy, having relapsed after at least 1 prior ITP therapy, or ineligible for other ITP therapies; prior therapy includes therapies
  • Age ≥ 1 year and \< 18 years at the time of providing
  • The mean of 2 counts taken during the screening period must be ≤ 30 x 10\^9/L with neither count > 35 x 10\^9/L
  • A serum creatinine concentration ≤ 1.5 times the laboratory normal range (for each age category) during the screening period
  • Adequate liver function; serum ≤ 1.5 times the laboratory normal range during the screening period; (AST) and alanine aminotransferase (ALT) ≤ 3.0 times the laboratory normal range during the screening period
  • > 10.0 g/dL during the screening period
  • Subject and/or subject's legally acceptable representative has provided informed consent prior to any study-specific procedure; subject has provided assent, where required

Exclusion criteria

Exclusion Criteria:

  • Known history of a bone marrow stem cell disorder; any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study
  • Known active or prior except adequately treated basal cell carcinoma
  • Known history of congenital thrombocytopenia
  • Known history of , , or (HIV)
  • Known history of H. pylori by urea breath test or stool antigen test within 6 months of enrollment or successfully treated with no evidence of infection
  • Known history of systemic lupus erythematosus, evans syndrome, or neutropenia
  • Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant
  • Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
  • Previous history of venous thromboembolism or thrombotic events
  • Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), Eltrombopag, recombinant human thrombopoietin (rHuTPO) or any producing agent
  • Rituximab (for any indication) or 6-mercaptopurine (6-MP) within 14 weeks before the screening visit, or anticipated use during the time of the proposed study
  • Splenectomy within 4 weeks of the screening visit
  • All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit
  • Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
  • Vaccinations known to decrease platelet counts within 8 weeks before the screening visit
  • Known to any recombinant E coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune)
  • Other criteria may apply
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.

    Drug: Romiplostim

  • Placebo comparator
    Placebo

    Participants received weekly subcutaneous placebo for 24 weeks.

    Drug: Placebo

Interventions

  • The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.

    Also known as: AMG 531, Nplate®

  • DrugPlacebo

    Matching placebo administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Durable Platelet Response

    A participant with durable platelet response was defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10\^9/L during the last 8 weeks of treatment (platelet counts obtained from week 18 to week 25). If a platelet count from a participant was not available (missing) in a certain week, that week was imputed as non-response for that participant. Platelet counts were not deemed as a positive response for 4 weeks after the administration of rescue medication.

    Time frame: Week 18 to week 25

Secondary outcomes

  1. Percentage of Participants With an Overall Platelet Response

    Overall platelet response is defined as either a durable platelet response or transient platelet response. Durable platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 6 or more times during week 18 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medication. Transient platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 4 or more times during week 2 to week 25 measurements but without durable platelet response. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.

    Time frame: Week 2 to week 25

  2. Number of Weeks With Platelet Response

    Number of weeks with platelet counts ≥ 50 x 10\^9/L during week 2 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.

    Time frame: Week 2 to week 25

  3. Percentage of Participants Who Received Rescue Medication During the Treatment Period

    Rescue medication is any medication (other than excluded medications) that is intended to increase platelet counts or prevent bleeding.

    Time frame: 24 weeks

  4. Total Number of Composite Bleeding Episodes

    A composite bleeding episode was defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinical significant bleeding event during weeks 2 through 25 of the treatment period. A clinically significant bleeding event was defined as a Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade ≥ 2 bleeding event.

    Time frame: Week 2 to week 25

  5. Number of Participants With Adverse Events

    A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life threatening (places the subject at immediate risk of death), * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other significant medical hazard. Adverse events were graded for severity according to the CTCAE version 3.0 grading scale, where Grade 3 = moderate, Grade 4 = life-threatening and Grade 5 = fatal. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to study drug. This relationship was determined by a "yes" or "no" response to the question: "Is there a reasonable possibility that the event may have been caused by study drug?"

    Time frame: From the first dose of study drug until 4 weeks after last dose; 28 weeks.

07

Results

Posted Jan 19, 2017

Participant flow

This study was conducted at 27 centers in the United States, Canada, and Australia. Participants were enrolled from 24 January 2012 to 03 September 2014.

Participant flow — Overall Study
MilestonePlaceboRomiplostim
Started2042
Received treatment1942
Completed1841
Not completed21
Withdrew: Ineligibility determined01
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryPercentage of Participants With a Durable Platelet Response

A participant with durable platelet response was defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10\^9/L during the last 8 weeks of treatment (platelet counts obtained from week 18 to week 25). If a platelet count from a participant was not available (missing) in a certain week, that week was imputed as non-response for that participant. Platelet counts were not deemed as a positive response for 4 weeks after the administration of rescue medication.

Time frame:
Week 18 to week 25
Reported as:
Number · percentage of participants
Percentage of Participants With a Durable Platelet Response
percentage of participantsPlaceboRomiplostim
Percentage of Participants With a Durable Platelet Response10.0 (1.2 to 31.7)52.4 (36.4 to 68.0)
Statistical analysis
  • Placebo vs Romiplostim · Cochran-Mantel-Haenszel · p = 0.0018 · Odds ratio (or): 9.0497 · 95% CI 1.896 to 43.199P-value from Cochran-Mantel-Haenszel test stratified by baseline age group.
SecondaryPercentage of Participants With an Overall Platelet Response

Overall platelet response is defined as either a durable platelet response or transient platelet response. Durable platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 6 or more times during week 18 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medication. Transient platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 4 or more times during week 2 to week 25 measurements but without durable platelet response. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.

Time frame:
Week 2 to week 25
Reported as:
Number · percentage of participants
Percentage of Participants With an Overall Platelet Response
percentage of participantsPlaceboRomiplostim
Percentage of Participants With an Overall Platelet Response20.0 (5.7 to 43.7)71.4 (55.4 to 84.3)
Statistical analysis
  • Placebo vs Romiplostim · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 9.0443 · 95% CI 2.535 to 32.265P-value from Cochran-Mantel-Haenszel test stratified by baseline age group.
SecondaryNumber of Weeks With Platelet Response

Number of weeks with platelet counts ≥ 50 x 10\^9/L during week 2 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.

Time frame:
Week 2 to week 25
Reported as:
Median · weeks
Number of Weeks With Platelet Response
weeksPlaceboRomiplostim
Number of Weeks With Platelet Response1.0 (0 to 22)12.0 (0 to 24)
Statistical analysis
  • Placebo vs Romiplostim · ANOVA · p = 0.0004P-value from Analysis of Variance with main effects (treatment and age group) model after testing for non-significant interaction (p-value ≥ 0.10).
SecondaryPercentage of Participants Who Received Rescue Medication During the Treatment Period

Rescue medication is any medication (other than excluded medications) that is intended to increase platelet counts or prevent bleeding.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Rescue Medication During the Treatment Period
percentage of participantsPlaceboRomiplostim
Percentage of Participants Who Received Rescue Medication During the Treatment Period45.0 (23.1 to 68.5)40.5 (25.6 to 56.7)
Statistical analysis
  • Placebo vs Romiplostim · Cochran-Mantel-Haenszel · p = 0.7103 · Odds ratio (or): 0.813 · 95% CI 0.277 to 2.391P-value from Cochran-Mantel-Haenszel test stratified by baseline age group
SecondaryTotal Number of Composite Bleeding Episodes

A composite bleeding episode was defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinical significant bleeding event during weeks 2 through 25 of the treatment period. A clinically significant bleeding event was defined as a Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade ≥ 2 bleeding event.

Time frame:
Week 2 to week 25
Reported as:
Mean · bleeding episodes
Total Number of Composite Bleeding Episodes
bleeding episodesPlaceboRomiplostim
Total Number of Composite Bleeding Episodes4.0 ± 6.91.9 ± 4.2
SecondaryNumber of Participants With Adverse Events

A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life threatening (places the subject at immediate risk of death), * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other significant medical hazard. Adverse events were graded for severity according to the CTCAE version 3.0 grading scale, where Grade 3 = moderate, Grade 4 = life-threatening and Grade 5 = fatal. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to study drug. This relationship was determined by a "yes" or "no" response to the question: "Is there a reasonable possibility that the event may have been caused by study drug?"

Time frame:
From the first dose of study drug until 4 weeks after last dose; 28 weeks.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPlaceboRomiplostim
Any adverse event (AE)1941
Serious adverse events (SAE)110
AE leading to discontinuation of study drug00
AE leading to discontinuation from study00
Grade 3 AE36
Grade 4 AE12
Grade 5 AE00
Treatment-related adverse events (TRAE)511
Treatment-related serious adverse events01
TRAE leading to discontinuation of study drug00
TRAE leading to discontinuation from study00
TRAE Grade 301
TRAE Grade 400
TRAE Grade 500

Adverse events

Collected over From the first dose of study drug until 4 weeks after last dose; 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/19 (5.3%)19/19 (100%)
Romiplostim—10/42 (23.8%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboRomiplostim
Animal BiteInjury, poisoning and procedural complications1/190/42
HaematuriaRenal and urinary disorders1/190/42
HeadacheNervous system disorders0/192/42
EpistaxisRespiratory, thoracic and mediastinal disorders0/192/42
ThrombocytosisBlood and lymphatic system disorders0/191/42
NauseaGastrointestinal disorders0/191/42
VomitingGastrointestinal disorders0/191/42
PyrexiaGeneral disorders0/191/42
BronchiolitisInfections and infestations0/191/42
Urinary Tract InfectionInfections and infestations0/191/42
Most frequent other events
Showing 10 of 117
Most frequent other events
EventPlaceboRomiplostim
HeadacheNervous system disorders11/1917/42
EpistaxisRespiratory, thoracic and mediastinal disorders10/1920/42
ContusionInjury, poisoning and procedural complications7/1921/42
Upper Respiratory Tract InfectionInfections and infestations5/1916/42
NauseaGastrointestinal disorders7/198/42
LacerationInjury, poisoning and procedural complications6/192/42
PetechiaeSkin and subcutaneous tissue disorders6/1910/42
FatigueGeneral disorders5/197/42
Mouth HaemorrhageGastrointestinal disorders4/1911/42
VomitingGastrointestinal disorders4/1911/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomiplostimTotal
Mean9.4 ± 4.79.7 ± 4.19.6 ± 4.3
Age, Customized
Age, Customized(participants)PlaceboRomiplostimTotal
≥ 1 - < 6 years4812
≥ 6 - < 12 years91827
≥ 12 - < 18 years71623
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomiplostimTotal
Female112435
Male91827
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRomiplostimTotal
American Indian or Alaska Native000
Asian235
Black or African American268
Multiple011
Native Hawaiian or Other Pacific Islander011
Other156
White152641
Platelets
Platelets(10^9/L)PlaceboRomiplostimTotal
Mean19.9 ± 19.317.5 ± 10.718.3 ± 13.9
08

Study locations

33 sites
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    New Orleans, Louisiana 70118, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    La Crosse, Wisconsin 54601, United States
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Parkville, Victoria 3052, Australia
  • Research Site
    Hamilton, Ontario L8S 4K1, Canada
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Montreal, Quebec H3H 1P3, Canada
  • Research Site
    Montreal, Quebec H3T 1C5, Canada
  • Research Site
    Quebec City, Quebec G1V 4G2, Canada
09

References and documents

Publications

  • Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18. PubMed 27103127 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 11 months after primary completion. A results delay was requested in Jan 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2011
First posted
Sep 30, 2011
Start
Jan 2012
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results delay requested
Jan 13, 2016
Results first posted
Jan 19, 2017
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01444417
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Jan 2012
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Jan 19, 2017
Last update
Feb 9, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion